Patient Gateway

RSS Feed

Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial

Tarlatamab-dlle Plus Durvalumab Improves Survival in First-Line ES-SCLC

First survival boost beyond immunotherapy alone in extensive-stage small cell lung cancer

Amgen: IMDELLTRA Imfinzi Combination Delivers Landmark Survival Gain in DeLLphi-305 Trial

Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC

AstraZeneca and Amgen clear a milestone in small cell lung cancer

AstraZeneca Says Imfinzi-Tarlatamab Combination Improves Survival in Extensive-Stage Small Cell Lung Cancer

AstraZeneca and Amgen clear a milestone in small cell lung cancer

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer